Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2022 - 08 - 22 save search
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
Published: 2022-08-22 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.54%
H: 1.57%
C: 1.57%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: -8.63%
H: 4.42%
C: 2.81%
opnt004 treatment patent
Global Fibromyalgia Treatment Market to Surpass US$ 4,079.0 Million by 2030 - Coherent Market Insights
Published: 2022-08-22 (Crawled : 19:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.56%
H: 0.62%
C: -0.82%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.98%
H: 0.21%
C: -0.85%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.91%
H: 0.1%
C: -0.17%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.58%
H: 0.19%
C: -1.91%
treatment global fibromyalgia market
Gas Treatment Market Size is Projected To Reach USD 4791.5 Million By 2028 at a CAGR of 4.6% - Valuates Reports
Published: 2022-08-22 (Crawled : 17:00) - prnewswire.com
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -1.59%
H: 0.31%
C: -2.41%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -2.76%
H: 0.02%
C: -1.91%
treatment market
Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain
Published: 2022-08-22 (Crawled : 14:00) - biospace.com/
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 0.0%
H: 1.81%
C: -6.25%
anjeso treatment patent application
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
Published: 2022-08-22 (Crawled : 14:00) - biospace.com/
DRTS | $2.635 -0.94% -0.95% 48K
|
n/a
|
| O: -2.4%
H: 0.41%
C: -2.97%
treatment collaboration tau dart software
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Published: 2022-08-22 (Crawled : 13:20) - biospace.com/
NERV | $2.5 1.2% 11K
|
Health Technology
|
| O: 5.96%
H: 57.75%
C: 39.51%
treatment fda drug schizophrenia application roluperidone negative
Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas
Published: 2022-08-22 (Crawled : 13:00) - globenewswire.com
SLRX | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: 3.67%
H: 0.0%
C: -12.5%
treatment ongoing trial seclidemstat phase 1
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: -3.08%
H: 6.35%
C: 3.17%
tnx-102 treatment covid study phase 2
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
Published: 2022-08-22 (Crawled : 13:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.15%
H: 1.08%
C: 0.25%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 5.44%
H: 3.53%
C: -7.93%
covid-19 treatment sabizabulin granted
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
Published: 2022-08-22 (Crawled : 12:00) - biospace.com/
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: -1.43%
H: 2.52%
C: 2.14%
treatment nephropathy ema application therapeutics review authorization
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
Published: 2022-08-22 (Crawled : 12:00) - biospace.com/
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: -1.43%
H: 2.52%
C: 2.14%
treatment nephropathy ema application therapeutics review authorization
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
Published: 2022-08-22 (Crawled : 10:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.2%
H: 0.06%
C: -1.3%
sunlenca treatment global hiv approval
Sciatica Treatment Market Size to Grow by USD 2.52 billion, Rising Awareness about Sciatica to Boost Market Growth - Technavio
Published: 2022-08-22 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.54%
H: 1.57%
C: 1.57%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.66%
H: 0.1%
C: -1.43%
TARO | $42.25 0.14% 0.0% 17K
|
Health Technology
|
| O: 0.78%
H: 0.77%
C: 0.53%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.54%
H: 0.36%
C: -1.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
treatment growth market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
DBRG | $17.3 0.06% 1.97% 1.2M
|
Finance and Insurance
OSK 4 | $117.72 0.05% 1.96% 370K
|
Producer Manufacturing
HYLN 4 | $1.29 -2.27% 1.55% 680K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.